ONCOLYTIC VIRUS-INFECTED IMMUNE CELLS AND METHODS OF USE
This disclosure is based, at least in part, on an unexpected discovery that oncolytic virus (e.g, myxoma virus)-infected tumor-specific T cells, expressing chimeric-antigen-receptor (CAR) or T-cell-receptor (TCR), are capable of inducing tumor cell autosis (in addition to T cell-induced apoptosis and pyroptosis) and/or overcoming primary and acquired resistance. The disclosed oncolytic virus (e.g, myxoma virus)-infected tumor-specific T cells represent a novel T-cell- cytotoxic machinery, and the unexpected synergy between T cells and oncolytic virus bolsters solid tumor cell autosis that reinforces tumor clearance..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 29. Feb. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LU YONG [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-02-29, Last update posted on www.tib.eu: 2024-04-10, Last updated: 2024-04-19 |
|---|
| Patentnummer: |
WO2024044628 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA001074520 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA001074520 | ||
| 003 | DE-627 | ||
| 005 | 20240419122643.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240322s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA001074520 | ||
| 035 | |a (EPA)WO2024044628 | ||
| 035 | |a (EPA)90014058 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LU YONG |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ONCOLYTIC VIRUS-INFECTED IMMUNE CELLS AND METHODS OF USE |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-02-29, Last update posted on www.tib.eu: 2024-04-10, Last updated: 2024-04-19 | ||
| 520 | |a This disclosure is based, at least in part, on an unexpected discovery that oncolytic virus (e.g, myxoma virus)-infected tumor-specific T cells, expressing chimeric-antigen-receptor (CAR) or T-cell-receptor (TCR), are capable of inducing tumor cell autosis (in addition to T cell-induced apoptosis and pyroptosis) and/or overcoming primary and acquired resistance. The disclosed oncolytic virus (e.g, myxoma virus)-infected tumor-specific T cells represent a novel T-cell- cytotoxic machinery, and the unexpected synergy between T cells and oncolytic virus bolsters solid tumor cell autosis that reinforces tumor clearance. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a MCFADDEN GRANT |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 29. Feb. |
| 773 | 1 | 8 | |g year:2024 |g day:29 |g month:02 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/90014058/publication/WO2024044628A1?q=WO2024044628 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 29 |c 02 | ||